Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2006

View Archived Issues

GTC awarded SBIR grant for work on CD137 monoclonal antibody

Aegerion signs crosslicense agreement for MTP inhibitors

Shire reviews six months ended June 30, 2006

Wockhardt reports the antibacterial potential of their novel oxazolidinones

Rotigotine transdermal patch yields reduction in RLS symptoms

Pivotal Yondelis study in ovarian cancer recommended to continue

SIGA Technologies terminates merger agreement with PharmAthene

Valentis and Urigen sign merger agreement

Sinclair Pharma and Intendis sign marketing agreement for Atopiclair

Virax advances towards phase II trial of VIR-201 therapeutic HIV vaccine

Pfizer to acquire PowderMed

Novel antihypertensives imparted by Novartis and NitroMed

New selective dual alpha1A/1D adrenoreceptor antagonists reported by Janssen

New agents for endocrine-related disorders imparted in recent patent literature

Completion of phase II Friedreich's ataxia study of idebenone

Clinical hold lifted on CX-717

Lofexidine studied for treatment of opiate withdrawal symptoms in phase III trial

Treatment under way in BrachySil study in inoperable pancreatic cancer

Omrix and NIAID sign avian influenza CRADA

TD-5108 begins phase II for GI motility dysfunction

Can-Fite to develop CF-102 for liver cancer

Ispinesib activity modest in head and neck squamous cell carcinoma

MK-0608: a robust and durable anti-HCV candidate

Adecatumumab assessed in phase II breast and prostate cancer trials

New topoisomerase inhibitor NSC-727357 exhibits antitumor activity

PharmaMar reports clinical results for kahalalide F, plitidepsin and trabectedin

Desoxypeganine shows good pharmacokinetic profile in healthy volunteers

Preclinical data of Basilea's novel macrolide BAL-19403 presented

Grapefruit juice consumption could help to prevent osteoporosis

R&D highlights from the UBS Global Life Sciences Conference in New York: Hana Biosciences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...